(19)
(11) EP 4 739 800 A1

(12)

(43) Date of publication:
13.05.2026 Bulletin 2026/20

(21) Application number: 24737764.1

(22) Date of filing: 27.06.2024
(51) International Patent Classification (IPC): 
C12Q 1/6886(2018.01)
(52) Cooperative Patent Classification (CPC):
C12Q 1/6886; C12Q 2600/158; C12Q 2600/112; C12Q 2600/118
(86) International application number:
PCT/EP2024/068197
(87) International publication number:
WO 2025/011978 (16.01.2025 Gazette 2025/03)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
GE KH MA MD TN

(30) Priority: 07.07.2023 EP 23382703

(71) Applicant: Reveal Genomics S.L.
08036 Barcelona (ES)

(72) Inventors:
  • PRAT APARICIO, Aleix
    08036 Barcelona (ES)
  • BRASÓ MARISTANY, Fara
    08036 Barcelona (ES)
  • PARÉ BRUNET, Laia
    08036 Barcelona (ES)

(74) Representative: Hoffmann Eitle 
Hoffmann Eitle S.L.U. Paseo de la Castellana 140, 3a planta Edificio LIMA
28046 Madrid
28046 Madrid (ES)

   


(54) IN VITRO METHOD FOR THE PROGNOSIS OF PATIENTS SUFFERING FROM TRIPLE-NEGATIVE BREAST CANCER